Investigating hepatitis B virus recurrence in post liver transplant patients a single center retrospective cohort study .
35th APASL, İstanbul, Türkiye, 22 - 25 Nisan 2026, ss.850-851, (Özet Bildiri)
- Yayın Türü: Bildiri / Özet Bildiri
- Basıldığı Şehir: İstanbul
- Basıldığı Ülke: Türkiye
- Sayfa Sayıları: ss.850-851
- Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet
Özet
Background / Hypothesis: Hepatitis B virus (HBV) infection is a primary indication for liver transplantation globally and in Türkiye, despite effective post-transplant prophylaxis (Hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogues (NUCs)). HBV recurrence still affects approximately 10% of recipients. High pre-transplant viral load, HBeAg positivity, and poor adherence to immunosuppression are known recurrence determinants. A comprehensive assessment of recurrence risk factors is essential to optimize post-transplant prophylaxis and improve long-term outcomes in high-risk patients. The present study aims to investigate the incidence and associated risk factors of HBV recurrence among Turkish patients who underwent living donor liver transplantation (LDLT) for HBV-related disease at Acıbadem Atakent Hospital in Türkiye. Materials and Methods: This retrospective, single-center cohort study includes records of all adult Turkish patients who underwent LDLT for HBV-related disease at Acıbadem Atakent Hospital between 2012 and 2025. Collected data include demographic, clinical, biochemical, virological, and pre-transplant tumor parameters, alongside specific HBV prophylactic and immunosuppressive protocols. Patient characteristics and HBV recurrence incidence will be summarized using descriptive statistics. Univariate and multivariate Cox regression analyses are planned to identify independent risk factors associated with HBV recurrence. Results will be presented with a 95% confidence interval (CI), and a pvalue of <0.05 will be considered statistically significant. Results: This study encompasses a single-center cohort of Turkish LDLT recipients with HBV-related disease, including patients through 2025. Anticipated results include a detailed incidence rate of HBV recurrence and the identification of independent risk factors, such as high pre-transplant HBV DNA levels and specific immunosuppressive drug use, which will be strongly correlated with recurrence risk. The findings are expected to highlight the critical role of standardized viral and immunological monitoring in preventing late recurrence, which has not been comprehensively addressed in this specific population. Conclusions: The successful completion of this study will provide crucial, high-impact data on the long-term management of HBV-related LDLT in a significant regional cohort. By pinpointing key pre- and posttransplant risk factors through robust multivariate analysis, our findings will offer actionable, evidencebased recommendations for optimizing prophylactic regimens and improving surveillance protocols. The derived risk stratification model will serve as an essential tool for clinicians in Türkiye and other regions with similar demographics, thereby leading to reduced HBV recurrence rates and significantly enhanced graft and patient survival in high-risk transplant recipients.